Evaluation of Macrophage Inflammatory Protein-1α as a Periodontal Disease Biomarker
NCT ID: NCT06016023
Last Updated: 2025-01-15
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
120 participants
OBSERVATIONAL
2023-09-01
2024-11-15
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Non-invasive Assessment of Inflammatory Markers MIP-1 Alpha and IL-6 in Saliva of Post Myocardial Infarction and Stage 4 Periodontitis Patients
NCT05314192
Impact of Periodontal Inflammation on Allostatic Load
NCT06978712
Effects of Periodontal Pathogens, Porphyromonas Gingivalis and Tannerella Forsythensis, on Cytokine Production From Human Monocyte-Derived Dendritic Cells
NCT00162838
Macrophage Markers in Periodontal and Peri-implant Health and Disease
NCT05242354
Effect of Periodontal Treatment on Inflammasome Proteins in Periodontal Diseases
NCT06075680
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Of late, chemokines have become the subject of interest for potential application as biomarkers for periodontal screening. MIP-1α is a cysteine-cysteine (C-C) chemokine that is secreted by a variety of cells like macrophages, fibroblasts, epithelial cells and endothelial cells. They principally serve to recruit leukocytes like monocytes, T lymphocytes, natural killer cells, dendritic cells and granulocytes to the site of inflammation. The primary challenge faced by researchers in analysis of host derived oral biomarkers in any sample fluid is the establishment of normal level of various biomarkers. This problem arises as the biomarkers that are found at exaggerated levels in periodontal inflammation are also detected in oral fluids in healthy periodontium but at a much lower value.
Hence, the current study has a two fold aim; first, to determine the feasibility of MIP-1α as a periodontal disease biomarker; and second, to correlate the value of MIP-1α obtained from oral rinse sample with the periodontal disease severity.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group 1: 30 periodontally healthy individuals.
Group 1 comprises of 30 periodontally healthy individuals who have never been clinically diagnosed with periodontitis.
No interventions assigned to this group
Group 2: 30 individuals with generalized gingivitis
Group 2 comprises of 30 participants diagnosed with generalized gingivitis according to the WWP 2017 classification.
No interventions assigned to this group
Group 3: 30 participants with generalised mild/moderate (STAGE I/II) periodontitis
Group 3 comprises of 30 participants, diagnosed with generalized mild/moderate (STAGE I/II) periodontitis, according to the WWP 2017 classification of periodontal disease.
No interventions assigned to this group
Group 4: 30 participants with generalized severe/very severe (STAGE III/IV) periodontitis
Group 4 comprises of 30 participants, diagnosed with generalized severe/very severe (STAGE III/IV) periodontitis, according to WWP 2017 classification of periodontal disease.
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients belonging to 4 groups -periodontally healthy, generalized gingivitis, generalized stage I/II periodontitis, generalized stage III/IV periodontitis
Exclusion Criteria
* Smokers and alcoholics
* Pregnant females
* Presence of xerostomia
* Patients with oral lesions or other contact sensitivity
* Patients suffering from autoimmune diseases such as Sjogren's syndrome, rheumatoid arthritis, systemic lupus erythematosus, systemic sclerosis
* Patients with acute or chronic use of medications that cause oral dryness
* Patients undergoing radiotherapy
* Patients with Grade C periodontitis
* Having received professional periodontal treatment within the previous 12 months
* Having received antibiotic medication 3 months prior to study
* Periapical pathology or other oral inflammatory conditions
* Cognitive disability (interfering with ability to give samples)
30 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Postgraduate Institute of Dental Sciences Rohtak
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
RINDA SHARMA, BDS
Role: PRINCIPAL_INVESTIGATOR
PT. B. D. SHARMA UHSR HARYANA
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Post Graduate Institute of Dental Sciences
Rohtak, Haryana, India
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
RINDAPERIO2023
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.